Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
Can a shot tame peanut allergies? small study tests xolair
Disease control CompletedThis phase 2 study tested the drug Xolair (omalizumab) in 11 people with peanut allergies who had already completed a previous trial. The goal was to see if the drug could reduce serious allergic reactions. Participants received regular injections of Xolair and reported any peanu…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New antibody drug shows promise for blocking asthma attacks
Disease control CompletedThis phase II trial tested a drug called huMAb OX40L in 29 adults with mild allergic asthma. The drug is an antibody designed to block a protein that triggers allergic reactions in the airways. Researchers measured whether it could prevent breathing problems caused by allergens, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 23, 2026 12:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called GDC-1971 in combination with either osimertinib (for non-small cell lung cancer) or cetuximab (for colorectal cancer). The study involved 10 participants with advanced or metastatic disease that had progressed after prior treatments…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New pill shrinks tough skin cancers in early trial
Disease control CompletedThis Phase II trial tested the drug vismodegib in 104 people with advanced basal cell carcinoma, a type of skin cancer that had spread or could not be surgically removed. Participants took a daily capsule until their cancer worsened or side effects became too severe. The study me…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
Cancer drug vismodegib tested for Long-Term use in small study
Disease control CompletedThis study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from cont…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New hope for tough blood cancers: drug combo shows promise
Disease control CompletedThis study tested a new drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with certain blood cancers (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia) that returned or didn't respond to prior treatment. The goal was to find the safe…
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New drug shows promise in cutting COPD attacks
Disease control CompletedThis study tested a drug called astegolimab in over 1,300 people with COPD who have frequent flare-ups. The goal was to see if adding this drug to standard care could reduce the number of moderate to severe COPD attacks over a year. Participants were current or former smokers wit…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
New combo therapy shows promise for advanced melanoma
Disease control CompletedThis study tested whether adding a personalized cancer vaccine (RO7198457) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated before. The trial involved 131 participants and measured how long th…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New study tests ocrelizumab in minority MS patients
Disease control CompletedThis study looked at how well ocrelizumab works in Black and Hispanic patients with relapsing multiple sclerosis (MS). About 179 participants received the drug and were monitored for relapses, disability progression, and brain lesions over 48 weeks. The goal was to see if the tre…
Phase: PHASE4 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
Personalized cancer vaccine shows promise in early trial
Disease control CompletedThis early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Promising new combo shows hope for lung cancer patients
Disease control CompletedThis study tested a new drug combination (tiragolumab plus atezolizumab) against a placebo plus atezolizumab in 135 people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combo could shrink tumors or delay cancer growth. P…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New hope for Tough-to-Treat myeloma? early trial tests cevostamab
Disease control CompletedThis early-phase trial tested a new drug called cevostamab in 355 people with multiple myeloma that had returned or stopped responding to other treatments. The main goal was to check the drug's safety and find the right dose. While it may help control the disease, it is not a cur…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New pill could quiet chronic cough in adults
Symptom relief CompletedThis study tested an experimental drug called GDC-6599 in 49 adults with chronic cough that persists despite treatment for asthma, COPD, or for unknown reasons. Participants took the drug or a placebo for two weeks, then switched. The goal was to see if the drug reduces cough fre…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Jun 23, 2026 22:03 UTC
-
New drug shows promise for relieving intense itch of skin disease
Symptom relief CompletedThis study tested an experimental drug called KPL-716 (vixarelimab) to see if it can reduce itching in people with prurigo nodularis, a skin condition that causes hard, itchy bumps. About 240 adults with moderate to severe itching took part. The goal was to measure how much the w…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Symptom relief
Last updated Jun 08, 2026 13:10 UTC
-
Comfort check: how do different injection methods for IgG compare?
Knowledge-focused CompletedThis study tested how well healthy adults tolerate immunoglobulin G (IgG) injections given under the skin. Researchers tried different injection conditions to see which caused the least pain and side effects. The goal was to gather information to improve future treatments for peo…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 23, 2026 22:04 UTC
-
Liver function and drug processing: a closer look at divarasib
Knowledge-focused CompletedThis study looked at how the drug divarasib is processed in the bodies of 31 people with different levels of liver function, from healthy to severely impaired. Participants received a single dose, and researchers measured drug levels in the blood over time. The goal was to unders…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:04 UTC
-
Healthy volunteers help test new drug formulations
Knowledge-focused CompletedThis early-stage study looked at how well two tablet versions of the experimental drug ZN-A-1041 are absorbed compared to a capsule form. It involved 18 healthy adults and also planned to check if food or a stomach-acid drug changes absorption, though that part was canceled. The …
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:51 UTC
-
Healthy volunteers test how breakfast and heartburn pills change new drug levels
Knowledge-focused CompletedThis study tested how food and a common stomach-acid drug (rabeprazole) affect the amount of an experimental medicine called ZN-A-1041 in the blood. Twenty-four healthy adults took the drug under different conditions to measure absorption. The goal was to learn how to best take t…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:04 UTC